ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Antibody-Suppressor CD8+ T Cells Ameliorate Antibody-Mediated Rejection Following Kidney Transplant in Mice

J. M. Zimmerer1, J. L. Han1, Q. Zeng2, B. A. Ringwald1, C. Cassol1, R. Warren1, M. Abdel-Rasoul1, C. K. Breuer2, G. L. Bumgardner1

1Ohio State University, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH

Meeting: 2020 American Transplant Congress

Abstract number: D-308

Keywords: Alloantibodies, Survival, T cells

Session Information

Session Name: Poster Session D: Cellular Therapies, Tissue Engineering / Regenerative Medicine

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: We previously reported the novel alloantibody suppressor activity of alloprimed CXCR5+IFN-γ+CD8+ T cells following hepatocellular transplant in mice. We utilized a murine kidney transplant (KTx) model and CCR5 KO recipient mice in order to investigate the role of these cells in suppression of alloantibody after a vascularized solid organ transplant. CCR5 KO KTx mice produce high titer alloantibody associated with severe antibody mediated rejection (AMR) that reproduces AMR histology observed in human KTx recipients. In the current studies, we investigated the biologic impact of adoptive cell transfer (ACT) of alloprimed CXCR5+IFN-γ+CD8+ T cells into high alloantibody producing CCR5 KO KTx recipients.

*Methods: CCR5 KO mice (H-2b) were transplanted with an allogeneic A/J (H-2a) kidney, and on postoperative day 5 underwent ACT of flow-sorted, alloprimed CXCR5+IFN-γ+CD8+ T cell subsets [retrieved from C57BL/6 mice alloprimed with A/J alloantigen (day 7)]. A second CCR5 KO KTx cohort received concomitant bilateral native nephrectomy in order to evaluate allograft survival by serial monitoring of serum creatinine (>100 μmol/L creatinine defines rejection). Untreated CCR5 KO recipients served as controls.

*Results: CCR5 KO KTx recipients developed high alloantibody titer (5,800±700, n=7) compared to wild-type recipients (1,200±100, n=9, p=0.0003). ACT of alloprimed CXCR5+IFN-γ+CD8+ T cells significantly inhibited alloantibody production in CCR5 KO recipients by 5-fold (1,200±200, p<0.0001). In addition, ACT of alloprimed CXCR5+IFN-γ+CD8+ T cells significantly inhibited day 14 AMR pathology (peritubular capillary margination and C4d deposition, arteritis) in CCR5 KO recipients (n=5) compared to untreated controls (n=5; composite histologic score 3.6±1.5 vs. 8.4±0.2, respectively; p=0.006). Alloantibody titer remained suppressed in treated mice greater than 30 days posttransplant, which correlated with a significant enhancement of allograft survival following ACT of alloprimed CXCR5+IFN-γ+CD8+ T cells (MST= 52 days, n=6) compared to untreated controls (MST= 14 days, n=5, p=0.006; see Figure).

*Conclusions: These data support the conclusion that ACT of antibody-suppressor CXCR5+IFN-γ+CD8+ T cells effectively inhibits alloantibody production and AMR not only after allogeneic hepatocellular transplant but also after vascularized solid organ transplant such as in CCR5 KO murine KTx recipients.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Zimmerer JM, Han JL, Zeng Q, Ringwald BA, Cassol C, Warren R, Abdel-Rasoul M, Breuer CK, Bumgardner GL. Antibody-Suppressor CD8+ T Cells Ameliorate Antibody-Mediated Rejection Following Kidney Transplant in Mice [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/antibody-suppressor-cd8-t-cells-ameliorate-antibody-mediated-rejection-following-kidney-transplant-in-mice/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences